November 28 2022

AAP of the ARC Foundation “Cancer and Aging”: Congratulations to Serge Adnot, from the team of G. Derumeaux, biological coordinator of the project, and Florence Canouï-Poitrine and Christos Chouaid from the team S. Bastuji-Garin, team associated with the project: “Identification of biomarkers of aging to better adapt the treatment of bronchial cancers in elderly subjects. A clinico-biological approach in 2 steps”, which has just been selected by the ARC Foundation

The objective of this call for proposals is to support translational research projects dedicated to understanding the specificities of cancer biology in elderly patients. The selected projects, co-sponsored by a biological leader and a clinical leader, may be supported for a maximum of €1,000,000 to €3,000,000 over a period of 6 years.   Summary of […]

Read more
November 4 2022

CEpiA team publishes study in the Oct. 28 Journal of Clinical Oncology on a two-step frailty assessment strategy for older patients with solid cancers

In elderly cancer patients, it is recommended that frailty screening be performed prior to cancer treatment in order to refer patients for further geriatric assessment. The clinical utility of frailty screening tools has not been evaluated. Using data from 1678 elderly patients (median age 81 years) with solid cancers included in the ELCAPA cohort, the […]

Read more
September 23 2022

Summer School IMRB-Metatox 2022

The second IMRB Summer School took place in the magnificent setting of the Domaine de Frémigny in the south of Essonne, France, from July 6 to 8, 2022. Organized by the IMRB and the Metatox team of the University of Paris Cité, it brought together more than thirty master students, doctoral students and post-doctoral fellows […]

Read more
September 12 2022

Congratulations to Joana Esteves de Lima, newly recruited as a research fellow at Inserm in Frédéric Relaix’s team!

Joana Esteves de Lima is a biology researcher, specialized in developmental biology, muscle stem cells and epigenetics, recently recruited at Inserm as a CR researcher in Prof. Frédéric Relaix’s research team “Biology of the neuromuscular system” at the Institut Mondor de Recherche Biomédicale.   After a course in Developmental Biology and Evolution in Portugal, she […]

Read more
September 1 2022

Jean-Michel Pawlotsky’s team wins two European calls for projects focused on artificial intelligence and liver pathologies

This team has very recently been awarded two European funding, “TANGERINE” and “GENIAL”. Pr Julien Calderaro, member of the team, is co-investigator in these two projects.   The TANGERINE project (TRANSCAN call for proposals) brings together 5 investigators (Spain, Germany, Israel, France, Romania) and aims to develop multimodal, pan-cancer artificial intelligence models for predicting response […]

Read more
July 11 2022

Visiting IMRB for her first official visit, Mrs. Sylvie RETAILLEAU, Minister of Higher Education and Research did not come empty-handed!

On the occasion of her first official visit to UPEC, Mrs. Sylvie Retailleau, Minister of Higher Education and Research was with us on Tuesday, July 5. She visited several laboratories and then went to the IMRB premises to congratulate Professor Marion Leboyer, IMRB-Translational Neuropsychiatry Team, for the PROPSY precision program in mental health supported by […]

Read more
July 4 2022

Congratulations to Laura Fertitta from the Mondor Neurofibromatosis Reference Center, Pierre Wolkenstein, CRN Mondor and IMRB-Gaulard team, and Piotr Topilko, IMRB-Gaulard team, who have just successfully applied to the prestigious Francis S. Collins Scholarship program at John Hopkins University!

Cutaneous neurofibromas (NFcut) are the most frequent complication of patients with Neurofibromatosis type 1 (NF1). Although benign, they are responsible for disfigurement, pruritus and suffering that is difficult to control and which can affect the quality of life of patients. Their removal (surgical excision, electrodissection, destruction with CO2 laser) is the only therapeutic option to […]

Read more
April 25 2022

Congratulations to Maëlle BRIOTTET, doctoral student in Sophie Lanone’s team in Valérie Urbach’s group, who received the Prize of the association Vaincre la Mucoviscidose during the French Symposium for Young Researchers

The Young Researchers’ Symposium mobilizes the French “muco” community around research. The 23rd edition took place this year on February 15, in a mixed format with a “remote” audience and a majority of speakers present at the association’s headquarters.   Twenty young researchers (selected by an ad hoc committee from 42 applications received) presented their […]

Read more
April 19 2022

Omicron variant: Vaccination reveals a strong but incomplete immune escape. A study signed by Matthieu Mahévas’ group within the France Pirenne team and published this month in Immunity

  The Omicron variant of SARS-CoV-2 can escape neutralization by vaccine-induced antibodies as well as by antibodies from convalescent plasma. Memory B cells (MBs) represent a protective bulwark against SARS-CoV-2 because they persist after infection and vaccination enhances their affinity. The ability of BMs, generated by mRNA vaccines, to recognize the Omicron variant remains unknown […]

Read more
April 8 2022

A new treatment for post-transplant leukemia relapse! A study by José Cohen’s I-BIOT team published this month in the Journal for Immunotherapy of cancer

Leukemia is a group of several types of blood cancer that affect up to 10,000 people in France each year. One of the proposed treatments is the transplant of hematopoietic stem cells. These cells are produced by the bone marrow and are the source of the various blood cells. Despite the success of this therapeutic […]

Read more
March 1 2022

The DIM One Health 2.0 project led by Inserm and Prof. Jean-Daniel Lelièvre, accredited by the Ile-de-France region

The COVID-19 pandemic is a reminder of the reality of so-called emerging infectious diseases. These diseases represent in a caricatural way the “One Health” concept of a single health shared by humans and animals in their environment. This concept, which has become obvious in recent years, is the subject of numerous national and international projects. […]

Read more
February 21 2022

Artificial intelligence predicts immune and inflammatory genetic signatures directly from hepatocellular carcinoma histology. A study led by Prof. Julien Calderaro and published in Journal of Hepatology

Immune gene signatures reflecting the quality and quantity of the intra-tumor immune infiltration are known to predict sensitivity to immunotherapy, but their use in the clinical setting is however challenging, as they require access to molecular biology platforms for the extraction of nucleic acids and their processing/sequencing. They are also highly dependent on sample quality […]

Read more
February 7 2022

The FRM labels Bijan Ghaleh’s team for its project “The heme as a danger molecule during myocardial infarction”.

The project led by Roberta Foresti, Roberto Motterlini, Sandrine Pons and Bijan Ghaleh, focuses on the release of Danger Associated Molecular Patten (DAMP) during myocardial infarction, in particular heme.   The main objective is to demonstrate the role of heme, as DAMP and as a signal for HO-1 activation to modulate inflammation, protect the myocardium […]

Read more
January 31 2022

Publication in Nature Medicine of the long-term results of the HGB-205 gene therapy trial for beta-hemoglobinopathies, conducted at the Necker Hospital and for which the analyses of patients with sickle cell disease were carried out by the France Pirenne team (N. Hebert, L. Kiger, P. Bartolucci).

  In the HGB-205 phase I/II clinical trial, four patients with transfusion-dependent beta thalassemia and three patients with sickle cell disease, aged 13 to 21 years, were treated with lentiviral gene therapy. They were followed for a median of 4.5 years.   The patients with beta thalassemia all became “transfusion independent” within the first month […]

Read more
January 24 2022

Publication in Lancet of the results of the SEPREVEN* study: randomized trial conducted in 12 neonatal intensive care units in France with the theme of patient safety.

Promoted by the CHIC of Créteil with the support of the CRC of the CHIC, the results of the SEPREVEN* study were published on January 21, 2022 in the journal The Lancet.   This study is the result of a collaborative effort: it was coordinated by Dr. Laurence Caeymaex, head of the neonatal intensive care […]

Read more